Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2013 | 8 | 4 | 369-376

Article title

Impact of melatonin on immunity: a review


Title variants

Languages of publication



Melatonin is a hormone produced by the pineal gland. In addition to its hormonal effect, it has strong antioxidant properties. Melatonin is probably best known for its ability to control circadian rhythm; it is sold in many countries as a supplement or drug for improving of sleep quality. However, melatonin’s effect is not limited to control of circadian rhythm:. it is involved in other effects, including cell cycle control and regulation of several important enzymes, including inhibition of inducible nitric oxide synthase. Melatonin affects immunity as well. It can modulate the immune response on disparate levels with a significant effect on inflammation. The role of melatonin in body regulatory process is not well understood; only limited conclusions can be drawn from known data. The current review attempts to summarize both basic facts about melatonin’s effects and propose research on the lesser known issues in the future.










Physical description


1 - 8 - 2013
12 - 6 - 2013


  • Faculty of Military Health Sciences, University of Defense, Trebesska 1575, 50001, Hradec Kralove, Czech Republic


  • [1] Ivanova TN, Iuvone PM. Melatonin synthesis in retina: circadian regulation of arylalkylamine N-acetyltransferase activity in cultured photoreceptor cells of embryonic chicken retina. Brain Res 2003; 973: 56–63 http://dx.doi.org/10.1016/S0006-8993(03)02540-X[Crossref]
  • [2] do Carmo Buonfiglio D, Peliciari-Garcia RA, do Amaral FG et al. Early-stage retinal melatonin synthesis impairment in streptozotocin-induced diabetic wistar rats. Invest Ophthalml Vis Sci 2011; 52: 7416–7422 http://dx.doi.org/10.1167/iovs.10-6756[Crossref]
  • [3] Konturek PC, Brzozowski T, Konturek SJ. Gut clock: implication of circadian rhythms in the gastrointestinal tract. J Physiol Pharmacol 2011; 62: 139–150
  • [4] Hasan S, Santhi N, Lazar AS et al. Assessment of circadian rhythms in humans: comparison of realtime fibroblast reporter imaging with plasma melatonin. Faseb J 2012; 26: 2414–2423 DOI: 10.1096/fj.11-201699 http://dx.doi.org/10.1096/fj.11-201699[Crossref]
  • [5] Smulevich AB, Dubnitskaya EB. A dimensional rhythmological model of depression. Z Nevrol Psikhiatrii Im S S Korsakova 2010; 110: 4–10
  • [6] Hur SP, Takeuchi Y, Itoh H et al. Fish sleeping under sandy bottom: Interplay of melatonin and clock genes. Gen Comp Endocrinol 2012; 177: 37–45 DOI: 10.1016/j.ygcen.2012.01.007 http://dx.doi.org/10.1016/j.ygcen.2012.01.007[Crossref]
  • [7] Barrett P, Bolborea M. Molecular pathways involved in seasonal body weight and reproductive responses governed by melatonin. J Pineal Res 2012; 52: 376–388 DOI: 10.1111/j.1600-079X.2011.00963.x http://dx.doi.org/10.1111/j.1600-079X.2011.00963.x[Crossref]
  • [8] Deregnaucourt S, Saar S, Gahr M. Melatonin affects the temporal pattern of vocal signatures in birds. J Pineal Res 2012; 53: 245–258 DOI: 10.1111/j.1600-079X.2012.00993.x http://dx.doi.org/10.1111/j.1600-079X.2012.00993.x[Crossref]
  • [9] Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 2006; 60: 97–108 DOI: 10.1016/j.biopha.2006.01.002 http://dx.doi.org/10.1016/j.biopha.2006.01.002[Crossref]
  • [10] Jaworek J, Szklarczyk J, Jaworek AK et al. Protective effect of melatonin on acute pancreatitis. Int J Inflam 2012; 2012: 173675
  • [11] Pohanka M. Alzheimer’s disease and related neurodegenerative disorders: implication and counteracting of melatonin. Journal of Applied Biomedicine 2011; 9: 185–196 DOI: DOI 10.2478/v10136-011-0003-6 [Crossref]
  • [12] Alonso-Vale MI, Andreotti S, Mukai PY et al. Melatonin and the circadian entrainment of metabolic and hormonal activities in primary isolated adipocytes. J Pineal Res 2008; 45: 422–429 http://dx.doi.org/10.1111/j.1600-079X.2008.00610.x[Crossref]
  • [13] Gumenyuk V, Roth T, Drake CL. Circadian phase, sleepiness, and light exposure assessment in night workers with and without shift work disorder. Chronobiol Int 2012; 29: 928–936 http://dx.doi.org/10.3109/07420528.2012.699356[Crossref]
  • [14] Bhatti P, Mirick DK, Davis S. Invited commentary: shift work and cancer. Am J Epidemiol 2012; 176: 760–763 http://dx.doi.org/10.1093/aje/kws311[Crossref]
  • [15] Rodriguez-Naranjo MI, Moya ML, Cantos-Villar E et al. Comparative evaluation of the antioxidant activity of melatonin and related indoles. J Food Compos Anal 2012; 28: 16–22 DOI: 10.1016/j.jfca.2012.07.001 http://dx.doi.org/10.1016/j.jfca.2012.07.001[Crossref]
  • [16] Ozturk G, Akbulut KG, Guney S et al. Age-related changes in the rat brain mitochondrial antioxidative enzyme ratios: Modulation by melatonin. Exp Gerontol 2012; 47: 706–711 DOI: 10.1016/j.exger.2012.06.011 http://dx.doi.org/10.1016/j.exger.2012.06.011[Crossref]
  • [17] Ozturk G, Coskun S, Erbas D et al. The effect of melatonin on liver superoxide dismutase activity, serum nitrate and thyroid hormone levels. Jpn J Physiol 2000; 50: 149–153 DOI: 10.2170/jjphysiol.50.149 http://dx.doi.org/10.2170/jjphysiol.50.149[Crossref]
  • [18] Cutando A, Aneiros-Fernandez J, Lopez-Valverde A et al. A new perspective in Oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. Arch Oral Biol 2011; 56: 944–950 http://dx.doi.org/10.1016/j.archoralbio.2011.03.004[Crossref]
  • [19] Dubocovich ML. Melatonin receptors: Role on sleep and circadian rhythm regulation. Sleep Med 2007; 8: S34–S42 DOI: 10.1016/j.sleep.2007.10.007 http://dx.doi.org/10.1016/j.sleep.2007.10.007[Crossref]
  • [20] Mor M, Rivara S, Pala D et al. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. Expert Opin Ther Pat 2010; 20: 1059–1077 http://dx.doi.org/10.1517/13543776.2010.496455[Crossref]
  • [21] Spadoni G, Bedini A, Rivara S et al. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther 2011; 17: 733–741 http://dx.doi.org/10.1111/j.1755-5949.2010.00197.x[Crossref]
  • [22] Vella F, Gilles FA, Delagrange P et al. NRH: quinone reductase 2: An enzyme of surprises and mysteries. Biochem Pharmacol 2005; 71: 1–12 DOI: 10.1016/j.bcp.2005.09.019 http://dx.doi.org/10.1016/j.bcp.2005.09.019[Crossref]
  • [23] Tan DX, Manchester LC, Terron MP et al. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J Pineal Res 2007; 43: 317–320 DOI: 10.1111/j.1600-079X.2007.00513.x http://dx.doi.org/10.1111/j.1600-079X.2007.00513.x[Crossref]
  • [24] Boutin JA, Marcheteau E, Henning P et al. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate. J Pineal Res 2008; 45: 524–531 http://dx.doi.org/10.1111/j.1600-079X.2008.00631.x
  • [25] Boutin JA, Saunier C, Guenin SP et al. Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis. Arch Biochem Biophys 2008; 477: 12–19 DOI: 10.1016/j. abb.2008.04.040 http://dx.doi.org/10.1016/j.abb.2008.04.040[Crossref]
  • [26] Reybier K, Perio P, Ferry G et al. Insights into the redox cycle of human quinone reductase 2. Free Radic Res 2011; 45: 1184–1195 DOI: 10.3109/10715762.2011.605788 http://dx.doi.org/10.3109/10715762.2011.605788[Crossref]
  • [27] Carbajo-Pescador S, Martin-Renedo J, Garcia-Palomo A et al. Changes in the expression of melatonin receptors induced by melatonin treatment in hepatocarcinoma HepG2 cells. J Pineal Res 2009; 47: 330–338 DOI: 10.1111/j.1600-079X.2009.00719.x http://dx.doi.org/10.1111/j.1600-079X.2009.00719.x[Crossref]
  • [28] Stehlin-Gaon C, Willmann D, Zeyer D et al. Alltrans retinoic acid is a ligand for the orphan nuclear receptor ROR beta. Nat Struct Biol 2003; 10: 820–825 DOI: 10.1038/nsb979 http://dx.doi.org/10.1038/nsb979[Crossref]
  • [29] Lardone PJ, Guerrero JM, Fernandez-Santos JM et al. Melatonin synthesized by T lymphocytes as a ligand of the retinoic acid-related orphan receptor. J Pineal Res 2011; 51: 454–462 DOI: 10.1111/j.1600-079X.2011.00909.x http://dx.doi.org/10.1111/j.1600-079X.2011.00909.x[Crossref]
  • [30] Missbach M, Jagher B, Sigg I et al. Thiazolidine diones, specific ligands of the nuclear receptor retinoid Z receptor/retinoid acid receptor-related orphan receptor alpha with potent antiarthritic activity. Journal of Biological Chemistry 1996; 271: 13515–13522 http://dx.doi.org/10.1074/jbc.271.23.13515[Crossref]
  • [31] Agez L, Laurent V, Pevet P et al. Melatonin affects nuclear orphan receptors mRNA in the rat suprachiasmatic nuclei. Neuroscience 2007; 144: 522–530 DOI: 10.1016/j.neuroscience.2006.09.030 http://dx.doi.org/10.1016/j.neuroscience.2006.09.030[Crossref]
  • [32] Kiefer TL, Lai L, Yuan L et al. Differential regulation of estrogen receptor alpha, glucocorticoid receptor and retinoic acid receptor alpha transcriptional activity by melatonin is mediated via different G proteins. J Pineal Res 2005; 38: 231–239 DOI: 10.1111/j.1600-079X.2004.00198.x http://dx.doi.org/10.1111/j.1600-079X.2004.00198.x[Crossref]
  • [33] Pohanka M. Antioxidants countermeasures against sulfur mustard. Mini-Rev Med Chem 2012; 12: 742–748 http://dx.doi.org/10.2174/138955712801264783[Crossref]
  • [34] Tamura EK, Cecon E, Monteiro AWA et al. Melatonin inhibits LPS-induced NO production in rat endothelial cells. J Pineal Res 2009; 46: 268–274 DOI: 10.1111/j.1600-079X.2008.00657.x http://dx.doi.org/10.1111/j.1600-079X.2008.00657.x[Crossref]
  • [35] Camacho ME, Carrion MD, Lopez-Cara LC et al. Melatonin synthetic analogs as nitric oxide synthase inhibitors. Mini-Rev Med Chem 2012; 12: 600–617 http://dx.doi.org/10.2174/138955712800626674[Crossref]
  • [36] Koh PO. Melatonin regulates nitric oxide synthase expression in ischemic brain injury. J Vet Med Sci 2008; 70: 747–750 DOI: 10.1292/jvms.70.747 http://dx.doi.org/10.1292/jvms.70.747[Crossref]
  • [37] Marczynski TJ, Yamaguchi N, Ling GM et al. Sleep induced by the administration of melatonin (5-methoxynacetyltryptamine) to the hypothalamus in unrestrained cats. Experimentia 1964; 20: 435–437 http://dx.doi.org/10.1007/BF02152134[Crossref]
  • [38] Pieri C, Marra M, Moroni F et al. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sciences 1994; 55: 271–276 http://dx.doi.org/10.1016/0024-3205(94)00666-0[Crossref]
  • [39] Pieri C, Moroni F, Marra M et al. Melatonin is an efficient antioxidant. Arch Gerontol Geriatr 1995; 20: 159–165 http://dx.doi.org/10.1016/0167-4943(94)00593-V[Crossref]
  • [40] Chen HY, Chen TY, Lee MY et al. Melatonin decreases neurovascular oxidative/nitrosative damage and protects against early increases in the blood-brain barrier permeability after transient focal cerebral ischemia in mice. J Pineal Res 2006; 41: 175–182 http://dx.doi.org/10.1111/j.1600-079X.2006.00351.x[Crossref]
  • [41] Shirazi A, Ghobadi G, Ghazi-Khansari M. A radiobiological review on melatonin: a novel radioprotector. J Radiat Res 2007; 48: 263–272 http://dx.doi.org/10.1269/jrr.06070[Crossref]
  • [42] Tan DX, Manchester LC, Terron MP et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42: 28–42 http://dx.doi.org/10.1111/j.1600-079X.2006.00407.x[Crossref]
  • [43] Fischer TW, Kleszczynski K, Hardkop LH et al. Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVRinduced depletion, and protects against the formation of DNA damage (8-hydroxy-2′-deoxyguanosine) in ex vivo human skin. J Pineal Res 2012; doi: 10.1111/jpi.12018 [Crossref]
  • [44] Shagirtha K, Muthumani M, Prabu SM. Melatonin abrogates cadmium induced oxidative stress related neurotoxicity in rats. Eur Rev Med Pharmacol Sci 2011; 15: 1039–1050
  • [45] Korkmaz GG, Uzun H, Cakatay U et al. Melatonin ameliorates oxidative damage in hyperglycemiainduced liver injury. Clinical and investigative medicine Medecine clinique et experimentale 2012; 35: E370
  • [46] Ali SA, Aly HF, Faddah LM et al. Dietary supplementation of some antioxidants against hypoxia. World J Gastroenterol 2012; 18: 6379–6386 http://dx.doi.org/10.3748/wjg.v18.i44.6379[Crossref]
  • [47] Karaoz E, Gultekin F, Akdogan M et al. Protective role of melatonin and a combination of vitamin C and vitamin E on lung toxicity induced by chlorpyrifosethyl in rats. Exp Toxicol Pathol 2002; 54: 97–108 http://dx.doi.org/10.1078/0940-2993-00236[Crossref]
  • [48] Yellon SM, Tran LT. Photoperiod, reproduction, and immunity in select strains of inbred mice. J Biol Rhythms 2002; 17: 65–75 http://dx.doi.org/10.1177/074873002129002348[Crossref]
  • [49] Zhang Z, Inserra PF, Liang B et al. Melatonin, immune modulation and aging. Autoimmunity 1997; 26: 43–53 http://dx.doi.org/10.3109/08916939709009549[Crossref]
  • [50] Santello FH, Frare EO, dos Santos CD et al. Suppressive action of melatonin on the TH-2 immune response in rats infected with Trypanosoma cruzi. J Pineal Res 2008; 45: 291–296 http://dx.doi.org/10.1111/j.1600-079X.2008.00589.x[Crossref]
  • [51] Brazao V, Del Vecchio Filipin M, Santello FH et al. Melatonin and zinc treatment: distinctive modulation of cytokine production in chronic experimental Trypanosoma cruzi infection. Cytokine 2011; 56: 627–632 http://dx.doi.org/10.1016/j.cyto.2011.08.037[Crossref]
  • [52] Xia MZ, Liang YL, Wang H et al. Melatonin modulates TLR4-mediated inflammatory genes through MyD88- and TRIF-dependent signaling pathways in lipopolysaccharide-stimulated RAW264.7 cells. J Pineal Res 2012; 53: 325–334 http://dx.doi.org/10.1111/j.1600-079X.2012.01002.x[Crossref]
  • [53] Lee YD, Kim JY, Lee KH et al. Melatonin attenuates lipopolysaccharide-induced acute lung inflammation in sleep-deprived mice. J Pineal Res 2009; 46: 53–57 http://dx.doi.org/10.1111/j.1600-079X.2008.00621.x[Crossref]
  • [54] Sinanoglu O, Sezgin G, Ozturk G et al. Melatonin with 1,25-Dihydroxyvitamin D3 Protects against Apoptotic Ischemia-Reperfusion Injury in the Rat Kidney. Ren Fail 2012; 34: 1021–1026 DOI: 10.3109/0886022x.2012.700887 http://dx.doi.org/10.3109/0886022X.2012.700887[Crossref]
  • [55] Cotto-Rios XM, Bekes M, Chapman J et al. Cell Rep. Deubiquitinases as a Signaling Target of Oxidative Stress 2012; doi: 10.1016/j.celrep.2012.11.011 [Crossref]
  • [56] Kodama R, Kato M, Furuta S et al. ROS-generating oxidases Nox1 and Nox4 contribute to oncogenic Ras-induced premature senescence. Genes Cells 2012; doi: 10.1111/gtc.12015 [Crossref]
  • [57] Liu RM, Choi J, Wu JH et al. Oxidative modification of nuclear mitogen-activated protein kinase phosphatase 1 is involved in transforming growth factor beta1-induced expression of plasminogen activator inhibitor 1 in fibroblasts. J Biol Chem 2010; 285: 16239–16247 http://dx.doi.org/10.1074/jbc.M110.111732[Crossref]
  • [58] Cutando A, Lopez-Valverde A, Arias-Santiago S et al. Role of melatonin in cancer treatment. Anticancer Res 2012; 32: 2747–2753
  • [59] Brigo F, Del Felice A. Melatonin as add-on treatment for epilepsy. Cochrane Database Syst Rev 2012; 6: CD006967
  • [60] Boga JA, Coto-Montes A, Rosales-Corral SA et al. Beneficial actions of melatonin in the management of viral infections: a new use for this ”molecular handyman”? Rev Med Virol 2012; 22: 323–338 DOI: 10.1002/rmv.1714 http://dx.doi.org/10.1002/rmv.1714[Crossref]
  • [61] Pohanka M. Acetylcholinesterase inhibitors: a patent review (2008 - present). Expert Opin Ther Pat 2012; 22: 871–886 DOI: 10.1517/13543776.2012.701620 http://dx.doi.org/10.1517/13543776.2012.701620[Crossref]
  • [62] Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2011; 155: 219–229 DOI: 10.5507/bp.2011.036 http://dx.doi.org/10.5507/bp.2011.036[Crossref]
  • [63] Martino M, Rocchi G, Escelsior A et al. Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance. Curr Neuropharmacol 2012; 10: 97–123 http://dx.doi.org/10.2174/157015912800604542
  • [64] Islam MA, Uddin MJ, Tholen E et al. Age-related changes in phagocytic activity and production of pro-inflammatory cytokines by lipopolysaccharide stimulated porcine alveolar macrophages. Cytokine 2012; 60: 707–717 DOI: 10.1016/j.cyto.2012.08.011 http://dx.doi.org/10.1016/j.cyto.2012.08.011[Crossref]
  • [65] van Besouw NM, Verjans G, Zuijderwijk JM et al. Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients. J Med Virol 2012; 84: 2018–2025 DOI: 10.1002/jmv.23427 http://dx.doi.org/10.1002/jmv.23427[Crossref]
  • [66] Rybka J, Kedziora-Kornatowska K, Kedziora J et al. Immunosenescence and late life depression. Centr Eur J Immunol 2009; 34: 271–275
  • [67] Manikonda PK, Jagota A. Melatonin administration differentially affects age-induced alterations in daily rhythms of lipid peroxidation and antioxidant enzymes in male rat liver. Biogerontology 2012; 13: 511–524 DOI: 10.1007/s10522-012-9396-1 http://dx.doi.org/10.1007/s10522-012-9396-1[Crossref]
  • [68] Rastmanesh R. Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity. Med Hypotheses 2011; 76: 79–85 DOI: 10.1016/j.mehy.2010.08.036 http://dx.doi.org/10.1016/j.mehy.2010.08.036[Crossref]
  • [69] Mozaffari S, Abdollahi M. Melatonin, a Promising Supplement in Inflammatory Bowel Disease: A Comprehensive Review of Evidences. Curr Pharm Design 2011; 17: 4372–4378 http://dx.doi.org/10.2174/138161211798999357[Crossref]
  • [70] Huai JP, Sun XC, Chen MJ et al. Melatonin attenuates acute pancreatitis-associated lung injury in rats by modulating interleukin 22. World Journal of Gastroenterology 2012; 18: 5122–5128 DOI: 10.3748/wjg.v18.i36.5122 http://dx.doi.org/10.3748/wjg.v18.i36.5122[Crossref]
  • [71] Srinivasan V, Spence DW, Trakht I et al. Immunomodulation by melatonin: Its significance for seasonally occurring diseases. Neuroimmunomodulation 2008; 15: 93–101 DOI: 10.1159/000148191 http://dx.doi.org/10.1159/000148191[Crossref]
  • [72] Lissoni P. Is there a role for melatonin in supportive care? Support Care Cancer 2002; 10: 110–116 DOI: 10.1007/s005200100281 http://dx.doi.org/10.1007/s005200100281[Crossref]
  • [73] Bekyarova G, Bratchkova Y, Tancheva S et al. Effective melatonin protection of burn-induced hepatic disorders in rats. Cent Eur J Med 2012; 7: 533–538 DOI: 10.2478/s11536-012-0006-z http://dx.doi.org/10.2478/s11536-012-0006-z[Crossref]
  • [74] Bekyarova G, Apostolova M, Kotzev I. Melatonin protection against burn-induced hepatic injury by down-regulation of nuclear factor kappa B activation Int J Immunopathol Pharmacol 2012; 25: 591–596
  • [75] Terry PD, Villinger F, Bubenik GA et al. Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research. Inflamm Bowel Dis 2009; 15: 134–140 DOI: 10.1002/ibd.20527 http://dx.doi.org/10.1002/ibd.20527[Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.